Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 20, 2019 09:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Initial Dosing of Phase I DDI Study of Intranasal Racemic Ketamine (SLS-002)

NEW YORK, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
November 18, 2019 08:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Receives FDA Fast Track Designation for Intranasal Racemic Ketamine (SLS-002)

NEW YORK, Nov. 18, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system...
November 08, 2019 07:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Reports Q3 2019 Pipeline Update

NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today released its third quarter pipeline update. “Seelos continued...
November 01, 2019 10:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics to Participate in Upcoming Investor Conferences in December

NEW YORK, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Evercore ISI 2nd...
October 21, 2019 09:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Amendment of SLS-002 Agreement

Seelos Plans to Study SLS-002 Initially in Suicidality in Major Depressive Disorder NEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage...
October 18, 2019 09:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics to Participate in Upcoming Investor Conference in November

NEW YORK, Oct. 18, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it will participate in the Jefferies 2019...
October 15, 2019 09:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces the Addition of Scott Applebaum as Lead Strategic Regulatory Consultant

NEW YORK, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today announced the addition of Scott Applebaum to its team as lead...
August 23, 2019 09:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Announces Pricing of $6.7 Million Registered Direct Offering

NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, announced today that it has entered into a securities purchase...
August 01, 2019 09:00 ET | Source: Seelos Therapeutics, Inc.

Seelos Therapeutics Reports Q2 2019 Pipeline Update

NEW YORK, Aug. 01, 2019 (GLOBE NEWSWIRE) -- Seelos Therapeutics, Inc. (NASDAQ: SEEL), a clinical-stage biopharmaceutical company, today released its second quarter pipeline update. “We have made...
November 10, 2016 19:00 ET | Source: MYnd Analytics, Inc.

Breakthrough Clinical Trial to be featured on CNN: Reductions in Suicidality, Depression, and Post-Traumatic Stress

MISSION VIEJO, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. ("MYnd") (OTCQB:MYAN), announces publication of “The Use of the Psychiatric Electroencephalography Evaluation Registry...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right